Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07549698 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Jun 2026 to Jul 17, 2026
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 1 of 3 entries
    • Site details revised at 4 of 10 sites
  2. Study sites: 8 to 10v4
  3. Trial sites expanded: 3 → 8 locationsv3
  4. Recruitment opened
    • Start date: Apr 2026 to Jun 2026
    • Trial sites expanded: 0 → 3 locations
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed/refractory primary Immune Thrombocytopenia (ITP) and relapsed/refractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).
Trial Details
NCT Number NCT07549698
Lead Sponsor CRISPR Therapeutics AG
Conditions
(from sponsor)		 Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
Related terms Purpura, Thrombocytopenic, Idiopathic
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov